Meeting
2024 ASCO Gastrointestinal Cancers Symposium
Serum angiopoietin-like protein 2 level in patients who received bevacizumab-containing chemotherapy for metastatic colorectal cancer.
Authors
Jung Hoon Kim
Pusan National University Yangsan Hospital, Yangsan-Si, South Korea
Jung Hoon Kim , Jae-Joon Kim , Sung Yong Oh , Sang-Bo Oh , Youngkyung Jeon , Kyung Wook Hong , Seung-Jin Kwag
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session C: Cancers of the Colon, Rectum, and Anus
Track
Colorectal Cancer,Anal Cancer
Sub Track
Tumor Biology, Biomarkers, and Pathology
Citation
J Clin Oncol 42, 2024 (suppl 3; abstr 209)
DOI
10.1200/JCO.2024.42.3_suppl.209
Abstract #
209
Poster Bd #
M17
Abstract Disclosures
Similar Posters
Poster
2018 Gastrointestinal Cancers Symposium
Plasma ICAM-1 (pICAM-1) and plasma IL-8 (pIL-8) level as biomarker of metastatic colorectal cancer patients (mCRC) treated with mFOLFOX6/XELOX plus bevacizumab (BV) (WJOG7612GTR).
First Author: Yoshiyuki Yamamoto
Poster
2016 Gastrointestinal Cancers Symposium
MAVERICC, a phase 2 study of mFOLFOX6-bevacizumab (BV) vs FOLFIRI-BV with biomarker stratification as first-line (1L) chemotherapy (CT) in patients (pts) with metastatic colorectal cancer (mCRC).
First Author: Heinz-Josef Lenz
Poster
2013 ASCO Annual Meeting
Primary tumor location and expression of mir-664 as a combined biomarker for bevacizumab effectiveness in metastatic colorectal cancer.
First Author: Mogens Karsboel Boisen
Poster
2024 ASCO Gastrointestinal Cancers Symposium
Impact of early tumor shrinkage and depth of response in patients with BRAF V600E-mutant metastatic colorectal cancer.
First Author: Shohei Udagawa